APA (7th ed.) Citation

Mateos, M., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., . . . Lonial, S. (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial. The lancet. Haematology, 6(9), . https://doi.org/10.1016/S2352-3026(19)30110-3

Chicago Style (17th ed.) Citation

Mateos, Maria-Victoria, et al. "Pembrolizumab Plus Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-label, Phase 3 Trial." The Lancet. Haematology 6, no. 9 (2019). https://doi.org/10.1016/S2352-3026(19)30110-3.

MLA (9th ed.) Citation

Mateos, Maria-Victoria, et al. "Pembrolizumab Plus Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (KEYNOTE-183): A Randomised, Open-label, Phase 3 Trial." The Lancet. Haematology, vol. 6, no. 9, 2019, https://doi.org/10.1016/S2352-3026(19)30110-3.